SLC16A3 and melanoma: For instance, inhibiting ALKBH5 may enhance the efficacy of anti-PD-1 therapy in melanoma patients by mediating the level of Mct4/Slc16a3, which is involved in regulating suppressive lymphocyte Treg and myeloid-derived suppressor cell accumulations in the TME (24).